about
Amniotic membrane: from structure and functions to clinical applications.Retinoblastoma: might photodynamic therapy be an option?Bisphosphonate-related osteonecrosis of the jaw: specificities.Clinical translation for endometrial cancer stem cells hypothesis.The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation.Ascorbic acid and colon cancer: an oxidative stimulus to cell death depending on cell profile.Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma.New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin.Effects of X-radiation on lung cancer cells: the interplay between oxidative stress and P53 levels.Influence of P53 on the radiotherapy response of hepatocellular carcinoma.Selective cytotoxicity and cell death induced by human amniotic membrane in hepatocellular carcinoma.Novel 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine fused chlorins as very active photodynamic agents for melanoma cells.Liver diseases: what is known so far about the therapy with human amniotic membrane?Targeting triple-negative breast cancer cells with 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles.Evaluation of a (99m) Tc-labelled meso-bisphenylporphyrin as a tumour image agent.Effect of amniotic membrane proteins in human cancer cell lines: an exploratory study.2-Bromo-5-hydroxyphenylporphyrins for photodynamic therapy: photosensitization efficiency, subcellular localization and in vivo studies.Synthesis of new 2-galactosylthiazolidine-4-carboxylic acid amides. Antitumor evaluation against melanoma and breast cancer cells.Chiral 6-hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles: novel antitumor DNA monoalkylating agents.Hypoxia-induced redox alterations and their correlation with 99mTc-MIBI and 99mTc-HL-91 uptake in colon cancer cells.In vitro photodynamic activity of 5,15-bis(3-hydroxyphenyl)porphyrin and its halogenated derivatives against cancer cells.Halogen atom effect on photophysical and photodynamic characteristics of derivatives of 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin.Chiral 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles with anti-breast cancer properties.A new therapeutic proposal for inoperable osteosarcoma: Photodynamic therapy.Mammospheres of hormonal receptor positive breast cancer diverge to triple-negative phenotype.Advances on photodynamic therapy of melanoma through novel ring-fused 5,15-diphenylchlorins.Platinum(II) Ring-Fused Chlorins as Near-Infrared Emitting Oxygen Sensors and Photodynamic Agents.Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells.Dental caries and bacterial load in saliva and dental biofilm of type 1 diabetics on continuous subcutaneous insulin infusion.Dibrominated camphoric acid derived salen complexes: Synthesis, characterization and cytotoxic activitySynthesis, characterization and assessment of the cytotoxic activity of Cu(II), Fe(III) and Mn(III) complexes of camphoric acid-derived salen ligandsSynthesis and biological evaluation of new naphthoquinone-containing pyrrolo-thiazoles as anticancer agentsSynthetic porphyrins bearing β-propionate chains as photosensitizers for photodynamic therapyBreast cancer circulating tumor cellsA look at clinical applications and developments of photodynamic therapyStudy of hepatocellular function in the murine model following hepatic artery selective clampingEfflux Pumps Modulation in Colorectal Adenocarcinoma Cell Lines: The Role of Nuclear MedicineHalogenated porphyrins as PDT sensitizers, something more than the heavy atom effect?Direct Pulp Capping: What is the Most Effective Therapy?—Systematic Review and Meta-AnalysisAmniotic membrane extract differentially regulates human peripheral blood T cell subsets, monocyte subpopulations and myeloid dendritic cells
P50
Q38010638-7AB9458D-2BCF-454F-99F5-A27765608B2BQ38314528-9C7D3B8D-12FF-4CCA-8C98-EC6FC101CAF7Q38493204-75246A18-B586-4906-9ACD-1FB02C00E49FQ38557171-F313E19C-47D3-41D3-8224-C3F803493406Q38730343-B8C2ACD4-C798-4C00-91AF-4D8D9B978F94Q38777806-1D4DCF63-88EF-45B4-8450-4229B4139F17Q38787238-76B3DB2B-F728-4F22-A89E-B3230CB6BBC4Q38788907-EDC58AFE-588F-4929-9B1A-D74C168D2C3EQ38818565-8FA19E97-E228-43D3-A15D-C07BBA682892Q38822712-1BC27BA8-7431-479C-910A-3F0F5ADE8567Q38824357-24EDAEE9-D109-45C6-9E0B-713D1AB71C9DQ38834482-74B80FE3-4F0F-49EE-995A-A430A737231AQ38934348-9807BDD5-B9B4-4642-8367-15A4D794AE38Q39002877-A0CDA84F-73AD-4A45-9513-8F2BBFDD22EDQ39014906-AE89736A-1757-4D6A-8399-D80200A84094Q39020188-A1F44F57-8F85-4A77-B879-C7965B01CCC2Q39184734-E06C46D0-4B72-46DC-91BA-7616126FD5C1Q39353511-55DFF051-C1D9-49E4-9CB6-E51F33512B25Q39668177-6987D3DD-2A0E-4200-8024-33C8FE84DDCBQ39740275-A613A34D-44AD-466C-953A-48047288F58AQ39776211-34C2A931-5B7B-484A-92FD-6561DB8EB6A4Q39973095-3C4CA479-2E30-42A2-94F2-7BCC9449D949Q44873668-BF334692-269F-4D3F-B6AD-E4232BB6F090Q47227373-733234DB-7F65-4A0C-84BF-8DDF76CC770FQ49572633-E72E7816-B3E4-4FFC-AAEA-68FE4A79E2C8Q50171348-5BA6440F-0B9B-46A5-B544-9163E4B13722Q50212581-E4AA52E5-7721-4F0E-92DF-7D9AF7FD1EDAQ51733896-F6ED6249-0609-479F-A511-0DEE58896E65Q55314654-B9270345-F0E3-4F4A-8EEB-A9F1A4E65A01Q57671990-9C88EB27-F625-4694-873D-D9BF2292C86FQ57672033-98316BD3-38E8-4181-988D-8E6C593CE4A2Q59153270-179E336E-B593-494F-AD8C-6375A0AA1678Q59153271-31AE1301-3FBF-46DF-9A4B-16AF297EBDE5Q59153272-C1339EC5-1E06-46D3-98C5-3D9B89F36D7FQ59153276-AD50C8FD-5E7F-497E-A03C-239C70484A53Q60196515-5C7AB531-0A0F-4368-8FC4-A29D3E3293BAQ60196573-9B3F0E30-FD59-4E47-8E8C-28D4A4A46806Q60196683-7A6C85AA-7968-4D50-B62C-904925261087Q61045805-B9F3CA62-DC28-4389-B321-DFB820946EE3Q63267768-39FB8159-8E08-48C9-9B19-BCD8A9B026FE
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mafalda Laranjo
@ast
Mafalda Laranjo
@en
Mafalda Laranjo
@es
Mafalda Laranjo
@nl
Mafalda Laranjo
@sl
type
label
Mafalda Laranjo
@ast
Mafalda Laranjo
@en
Mafalda Laranjo
@es
Mafalda Laranjo
@nl
Mafalda Laranjo
@sl
altLabel
M Laranjo
@en
prefLabel
Mafalda Laranjo
@ast
Mafalda Laranjo
@en
Mafalda Laranjo
@es
Mafalda Laranjo
@nl
Mafalda Laranjo
@sl
P1053
C-4966-2008
P106
P1153
24338401200
P21
P2798
P31
P3829
P3835
mafalda-laranjo
P496
0000-0003-0689-6007